Urogen Pharma (NASDAQ:URGN) Trading Up 5.6%

Urogen Pharma Ltd (NASDAQ:URGN)’s share price was up 5.6% during mid-day trading on Tuesday . The stock traded as high as $34.32 and last traded at $34.04, approximately 176,695 shares were traded during trading. A decline of 4% from the average daily volume of 184,357 shares. The stock had previously closed at $32.24.

Several research analysts have issued reports on URGN shares. JPMorgan Chase & Co. started coverage on Urogen Pharma in a research note on Thursday, May 30th. They set a “neutral” rating and a $41.00 price objective for the company. HC Wainwright set a $75.00 price objective on Urogen Pharma and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Goldman Sachs Group started coverage on Urogen Pharma in a research note on Wednesday, May 29th. They set a “neutral” rating and a $50.00 price objective for the company. Zacks Investment Research lowered Urogen Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Finally, Cowen reiterated a “buy” rating on shares of Urogen Pharma in a research note on Monday, May 6th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Urogen Pharma currently has an average rating of “Buy” and a consensus price target of $59.00.

The firm has a market cap of $447.08 million, a P/E ratio of -7.09 and a beta of 1.21. The company’s 50 day simple moving average is $33.26.



Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Friday, August 9th. The company reported ($1.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.20) by $0.12. The business had revenue of $0.02 million during the quarter. As a group, research analysts forecast that Urogen Pharma Ltd will post -5.37 earnings per share for the current year.

Large investors have recently made changes to their positions in the company. Public Employees Retirement Association of Colorado acquired a new stake in shares of Urogen Pharma in the first quarter valued at $41,000. Bank of Montreal Can acquired a new stake in shares of Urogen Pharma in the second quarter valued at $56,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Urogen Pharma by 100.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,000 shares of the company’s stock valued at $74,000 after buying an additional 1,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Urogen Pharma by 112.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock valued at $89,000 after buying an additional 1,282 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Urogen Pharma in the second quarter valued at $170,000. Institutional investors own 97.61% of the company’s stock.

About Urogen Pharma (NASDAQ:URGN)

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Featured Story: Technical Indicators – What is a Golden Cross?

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.